Esophagus cancer postoperative early-stage recurrence and prognosis related miRNA marker and its application

Abstract

The invention discloses an esophagus cancer postoperative early-stage recurrence and prognosis related miRNA marker and its application, and concretely discloses an miRNA marker has-miR-382, an application of the miRNA marker in the making of an esophagus cancer postoperative early-stage recurrence and prognosis auxiliary diagnosis kit, an application of the primer of the esophagus cancer postoperative early-stage recurrence and prognosis related miRNA marker in the making of the esophagus cancer postoperative early-stage recurrence and prognosis auxiliary diagnosis kit, and the esophagus cancer postoperative early-stage recurrence and prognosis auxiliary diagnosis kit of the primer of the esophagus cancer postoperative early-stage recurrence and prognosis related miRNA marker. A screening method in the invention is simple and is convenient to operate, and the screened has-miR-382 can auxiliarily determine the prognosis or death risk of an esophagus cancer patient, and promotes the development of the esophagus cancer diagnosis and treatment.

Description

technical field [0001] The invention relates to a miRNA marker related to the early recurrence and prognosis of esophageal cancer after surgery, and also relates to the application of the marker, belonging to the fields of genetic engineering and oncology. Background technique [0002] Esophageal cancer (Esophageal carcinoma, EC) is a common malignant tumor of the digestive tract, accounting for the second place in the death of tumors in various parts of the digestive system. The world dies from this disease every year, reaching 300,000 people, of which about 150,000 people die in China every year. It is the country with the highest incidence rate of esophageal cancer in the world. Although great progress has been made in chemotherapy, radiotherapy, and concurrent chemoradiotherapy for esophageal cancer in recent years, surgery is still the most important treatment for esophageal cancer. However, the treatment effect is not ideal, and the 5-year survival rate is only about ...

AI Technical Summary

Problems solved by technology

[0004] At present, there are many studies and reports on tumor molecular markers of esophageal cancer, except for the traditional tumor markers carcinoembryonic antigen (CEA), squamous cell carcinoma-related antigen (SCC), cytokeratin fragment 19 (CYFRA2l–l ), p53 protein antibody (p53-Ab), etc., hot molecular markers EGFR (epidermal growth factor receptor), CycIinDl (cyclin Dl), COX-2 (cyclooxygenase 2), PCNA ( Proliferating cell nuclear antigen), VEGF (vascular endothelial growth factor) and so on all have certain clinical significance in judging the prognosis of esophageal cancer, but the above molecular markers mainly focus on the research on different tumor pathological stages, as well as on lymph node metastasis and tumor infiltration depth. There is a lack of research on molecular markers with different prognosis for the same pathological stage, the same operator, the same operation method, and the same postoperative treatment plan. There is a lack of research on early recurrence and metastasis of esophageal cancer after surgery. There is a lack of specificity. Molecular markers with high sensitivity and high sensitivity can be used to predict the occurrence, development and prognosis of esophageal cancer, and the process of esophageal cancer and development is the result of polygenic changes, and the molecular biological changes are not completely the same. The combination of molecular marker detection is helpful. To improve the sensitivity of judging the prognosis

Images